Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

On Monday, Veru Inc (VERU) stock saw a decline, ending the day at $0.64 which represents a decrease of $-0.57 or -47.11% from the prior close of $1.21. The stock opened at $0.64 and touched a low of ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company Monday announced positive topline results from the Phase 2b ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...